Critical reviews in oncology/hematology最新文献

{"title":"The roles of immune cells and non-immune cells in pre-metastatic niche of breast cancer","authors":"Qiao Zheng ,&nbsp;Tiecheng Zhou ,&nbsp;Dejiao Yao","doi":"10.1016/j.critrevonc.2025.104744","DOIUrl":"10.1016/j.critrevonc.2025.104744","url":null,"abstract":"<div><div>Distant metastasis is a pivotal and important event in patients with breast cancer, and inhibition of metastasis has always been the focus of clinical research. Recent advances have established that the metastasis of breast cancer is exacerbated not only by cancer cells and the tumor microenvironment but also by the pre-metastatic niche (PMN). Primary tumor secretory factors, immune cells including bone marrow-derived cells mobilized by tumors and non-immune cells within the local matrix microenvironment of the host are three key factors for PMN formation. This article reviews the roles of bone marrow-derived cells, lymphocytes, fibroblasts, endothelial cells, epithelial cells and cancer stem cells in the establishment of PMN before metastasis to further understand the metastasis mechanism of breast cancer and to explore clues for the inhibition of distant metastasis. Different cells play distinct but important roles in the establishment of the PMN and the induction of breast cancer metastasis. The interaction between different cells and tumor cells determines whether CTCs can be attached, survive and proliferate to promote distant metastasis.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"211 ","pages":"Article 104744"},"PeriodicalIF":5.5,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143863456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of the contribution of clinical and genetic factors to the racial disparity in taxane-induced peripheral neuropathy","authors":"Nam Nguyen-Hoang ,&nbsp;Maisa Nazzal ,&nbsp;Bryan P. Schneider ,&nbsp;Meghna S. Trivedi ,&nbsp;Daniel L. Hertz","doi":"10.1016/j.critrevonc.2025.104739","DOIUrl":"10.1016/j.critrevonc.2025.104739","url":null,"abstract":"<div><div>Taxanes are first-line chemotherapy for several solid tumors, but their use is often limited by taxane-induced peripheral neuropathy (TIPN), which can cause acute symptoms in up to 70 % of patients and severely deteriorate long-term quality of life. Recent evidence from large prospective observational studies confirms a dramatic racial disparity, with Black/African-ancestry patients facing roughly two times greater risk of TIPN compared to White patients. Understanding the root causes of this disparity is a critical first step toward eliminating inequities in cancer treatment side effects, aligning with a major goal of the U.S. National Cancer Institute’s National Cancer Plan. This review examines clinical and genetic factors contributing to racial differences in TIPN, focusing on those that have been associated with TIPN risk and are more prevalent within Black/African-ancestry individuals. Pre-existing neuropathy, vitamin D insufficiency, metabolic risk factors (obesity/diabetes), systemic taxane exposure, and genetic variants are discussed as potential contributors to this racial disparity. The review concludes by describing additional research that is needed to determine which of these factors are responsible for this disparity and what types of translational clinical studies could be conducted to target these mechanisms and reduce inequity. These findings could inform clinical strategies that improve long-term quality of life and promote health equity in taxane-treated cancer patients in the U.S. and globally.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"211 ","pages":"Article 104739"},"PeriodicalIF":5.5,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PD-1/PD-L1 inhibitors combined with anti-angiogenic drugs for advanced triple-negative breast cancer: Synergistic mechanisms and research progress","authors":"Rui Xu ,&nbsp;Shaowei Guo ,&nbsp;Qingle Song ,&nbsp;Xiaotong Wang ,&nbsp;Qingxia Li","doi":"10.1016/j.critrevonc.2025.104740","DOIUrl":"10.1016/j.critrevonc.2025.104740","url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC), a subtype of breast cancer that is highly aggressive and lacks effective therapeutic targets, has a particularly grim prognosis, with advanced patients having a significantly shorter median survival and showing resistance to chemotherapy. The introduction of immunotherapy has brought new hope for cancer treatment, but the use of immune checkpoint inhibitors（ ICI） alone in TNBC is ineffective, and there is an urgent need to explore more effective combination therapies.The combination of PD-1/PD-L1 inhibitors and anti-angiogenic drugs（AADs） can produce synergistic effects and open up new therapeutic avenues for TNBC patients. Specifically, inhibition of the vascular endothelial growth factor（VEGF） signaling pathway induces normalization of tumor vasculature, which in turn promotes infiltration of CD8 + T lymphocytes(CD8 + T cells）. Meanwhile, PD-1/PD-L1 inhibitors can similarly promote normalization of tumor vasculature and enhance the function of effector T cells by activating effector T cells and upregulating γ-interferon (IFN-γ) secretion. This combination regimen has demonstrated encouraging efficacy in several clinical studies. In this article, we comprehensively analyze the latest advances in the field,and provides insights into the application, mechanism of action, signaling pathways, clinical translational prospects, and shortcomings of anti-PD-1/PD-L1 drugs combined with anti-angiogenic drugs in advanced TNBC. This study aims to provide clues for the individualized treatment of TNBC, with a view to realizing precision medicine, reducing the risk of recurrence and metastasis in patients, and improving the poor prognosis, which has an important clinical practice value.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"211 ","pages":"Article 104740"},"PeriodicalIF":5.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic, prognostic, and metastatic value of chemokines as biomarkers for oral squamous cell carcinoma and their precursor lesions – A systematic review","authors":"Timothy Braun ,&nbsp;Abhimanyu Bisht ,&nbsp;Christopher Zhu,&nbsp;Majdy Idrees,&nbsp;Faris Alabeedi,&nbsp;Omar Kujan","doi":"10.1016/j.critrevonc.2025.104738","DOIUrl":"10.1016/j.critrevonc.2025.104738","url":null,"abstract":"<div><div>Oral cancer remains a significant public health concern, with many patients diagnosed at advanced stages and facing poor prognoses. Despite advances in cancer research, diagnosis has seen only limited improvements, with biopsies still being the primary reliable method. This systematic review investigates the role of chemokines as potential biomarkers for early detection, prognosis, and metastasis in oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMDs). Through an extensive literature search of MEDLINE, EMBASE, PubMed, and Scopus, 3350 articles were initially identified. After eliminating duplicates and screening for eligibility, 50 high-quality studies were included, offering a comprehensive overview of chemokine research in OSCC and OPMDs. Key findings indicate that CCR7 shows significant promise as a diagnostic, prognostic, and metastatic marker, although its function in precancerous conditions remains inadequately understood. CXCL10 and CCL22 were also highlighted for their strong prognostic and metastatic relevance, while CXCR4 and CXCL12 were identified as critical indicators of OSCC metastasis. Other chemokines, such as CXCR2, CCR4, XCR1, CXCL13, and CCL2 can aid OSCC differentiation and staging. However, the review emphasises the limitations of small patient cohorts and the lack of longitudinal research, stressing the need for further studies. Additionally, there is a pressing gap in research addressing chemokines as biomarkers for OPMDs. Rigorous validation is crucial to establish these biomarkers’ reliability and clinical utility across various stages of oral cancer development.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"211 ","pages":"Article 104738"},"PeriodicalIF":5.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-treatment adverse events ranking in targeted immunotherapy for hepatocellular carcinoma: A network meta-analysis based on risk probability assessment","authors":"Gaoyuan Yang ,&nbsp;Yupeng Ren ,&nbsp;Yuxuan Li ,&nbsp;Yongchang Tang ,&nbsp;Feng Yuan ,&nbsp;Mingbo Cao ,&nbsp;Zhiwei He ,&nbsp;Xiaorui Su ,&nbsp;Zheng Shi ,&nbsp;Ziyi Hu ,&nbsp;Meihai Deng ,&nbsp;Jie Ren ,&nbsp;Zhicheng Yao","doi":"10.1016/j.critrevonc.2025.104737","DOIUrl":"10.1016/j.critrevonc.2025.104737","url":null,"abstract":"<div><h3>Background</h3><div>Despite the rapid evolution of targeted and immunotherapies for hepatocellular carcinoma (HCC), a systematic comparison of their adverse event profiles remains limited. This review addresses this critical gap by synthesizing data from 13 randomized controlled trials (RCTs) to prioritize treatment regimens on the basis of safety, thereby guiding clinical decision-making in an era of expanding therapeutic options.</div></div><div><h3>Methods</h3><div>Clinical studies focusing on targeted and immunotherapies in HCC patients were chosen from databases such as PubMed, Embase, Web of Science and the Cochrane Library, which spans from 2008 to 2023. Data processing and evaluation followed PRISMA guidelines, with a random-effects model employed to merge the data. Network models were then developed, with adverse events serving as the primary endpoint for analysis.</div></div><div><h3>Results</h3><div>A comprehensive review of the relevant literature was conducted, identifying 13 randomized controlled trials (RCTs) encompassing 13 treatment protocols for HCC. This study included a total of 10,760 patients. Adverse events within the same category were initially consolidated, followed by the sequential construction of a network model to assess the risk probabilities associated with different targeted immunotherapy regimens for various adverse events and establish priority rankings.</div></div><div><h3>Conclusions</h3><div>Cabozantinib, camrelizumab, and their combination therapy for HCC are associated with a higher incidence of common adverse reactions, whereas durvalumab, lenvatinib, and their combination therapy are less likely to cause common adverse effects.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"211 ","pages":"Article 104737"},"PeriodicalIF":5.5,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143863457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surface-Enhanced Raman Scattering (SERS) combined with machine learning enables accurate diagnosis of cervical cancer: From molecule to cell to tissue level","authors":"Biqing Chen ,&nbsp;Jiayin Gao ,&nbsp;Haizhu Sun,&nbsp;Zhi Chen,&nbsp;Xiaohong Qiu","doi":"10.1016/j.critrevonc.2025.104736","DOIUrl":"10.1016/j.critrevonc.2025.104736","url":null,"abstract":"<div><div>The rising number of cervical cancer cases is placing a heavy economic strain on the country and its people. Improving survival rates hinges on early detection, precise diagnosis, and thorough treatment. Common screening and diagnostic methods like Pap smears, HPV testing, colposcopy, and histopathological exams are used in clinical practice, but they are often costly, time-consuming, invasive, subjective, and may lack the necessary sensitivity and specificity for accurate diagnosis. Developing a quick, non-invasive, and precise method for cervical cancer screening is crucial. Raman spectroscopy offers structural insights without damaging samples, but its weak signals and interference from biological fluorescence limit its clinical use. Surface-Enhanced Raman Scattering (SERS) overcomes these challenges, and recent advances, especially when combined with machine learning, enhance cervical cancer diagnosis by enabling precise detection of tumor. This paper comprehensively reviews and summarizes the application of SERS in cervical cancer diagnosis, ranging from molecular biomarker detection to live cell level and then to tissue level diagnosis. By integrating with machine learning, it facilitates the development of accurate, non-invasive diagnosis of cervical cancer.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"211 ","pages":"Article 104736"},"PeriodicalIF":5.5,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting TIME in advanced hepatocellular carcinoma: Mechanisms of drug resistance and treatment strategies","authors":"Xinyi Ye,&nbsp;Xizhu Fang,&nbsp;Fangfang Li,&nbsp;Dan Jin","doi":"10.1016/j.critrevonc.2025.104735","DOIUrl":"10.1016/j.critrevonc.2025.104735","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer. While early-stage HCC can be effectively managed with surgical resection and other interventions, treatment options for advanced HCC are limited. Current systemic treatments for advanced HCC include VEGF-targeted tyrosine kinase inhibitors (Sorafenib, Lenvatinib), and the combination therapy of anti PD-1/PD-L1 and anti VEGF (Atezolizumab plus Bevacizumab, Camrelizumab plus Rivoceranib). However, the lack of response to these drugs and the emergence of acquired drug resistance significantly impairs their efficacy. Numerous studies have demonstrated that the tumor immune microenvironment (TIME) plays a crucial role in modulating the response to these therapies. Various immune cells and their secreted factors within the TIME play a pivotal role in the emergence of secondary drug resistance in HCC. This article reviews the mechanism of TIME promoting drug resistance, discusses the influence of current systemic HCC treatment drugs on TIME, and evaluates how these TIME changes affect the efficacy of treatment. A deeper understanding of the interaction between TIME and systemic treatment drugs may be beneficial to enhance the treatment effect, mitigate drug resistance of advanced HCC, and ultimately improve the prognosis of patients.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"211 ","pages":"Article 104735"},"PeriodicalIF":5.5,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143863455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic landscapes drive CAR-T cell kinetics and fate decisions: Bridging persistence and resistance","authors":"Kecheng Wang ,&nbsp;Kaixin Ou ,&nbsp;Yifei Zeng ,&nbsp;Chunyan Yue ,&nbsp;Yaqi Zhuo ,&nbsp;Langqi Wang ,&nbsp;Huifang Chen ,&nbsp;Sanfang Tu","doi":"10.1016/j.critrevonc.2025.104729","DOIUrl":"10.1016/j.critrevonc.2025.104729","url":null,"abstract":"<div><div>Chimeric antigen receptor-T (CAR-T) cell therapy has revolutionized the treatment paradigm for B-cell malignancies and holds promise for solid tumor immunotherapy. However, CAR-T-cell therapy still faces many challenges, especially primary and secondary resistance. Some mechanisms of resistance, including CAR-T-cell dysfunction, an inhibitory tumor microenvironment, and tumor-intrinsic resistance, have been identified in previous studies. As insights into CAR-T-cell biology have increased, the role of epigenetic reprogramming in influencing the clinical effectiveness of CAR-T cells has become increasingly recognized. An increasing number of direct and indirect epigenetic targeting methods are being developed in combination with CAR-T-cell therapy. In this review, we emphasize the broad pharmacological links between epigenetic therapies and CAR-T-cell therapy, not only within CAR-T cells but also involving tumors and the tumor microenvironment. To elucidate the mechanisms through which epigenetic therapies promote CAR-T-cell therapy, we provide a comprehensive overview of the epigenetic basis of CAR-T-cell kinetics and differentiation, tumor-intrinsic factors and the microenvironment. We also describe some epigenetic strategies that have implications for CAR-T-cell therapy in the present and future. Because targeting epigenetics can have pleiotropic effects, developing more selective and less toxic targeting strategies and determining the optimal administration strategy in clinical trials are the focus of the next phase of research. In summary, we highlight the possible mechanisms and clinical potential of epigenetic regulation in CAR-T-cell therapy.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"211 ","pages":"Article 104729"},"PeriodicalIF":5.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: A systematic review and meta-analysis","authors":"Qibin Wu ,&nbsp;Xia Zhao ,&nbsp;Chong Yang ,&nbsp;Yinglin Yuan ,&nbsp;Hongji Yang ,&nbsp;Qiang Fu","doi":"10.1016/j.critrevonc.2025.104730","DOIUrl":"10.1016/j.critrevonc.2025.104730","url":null,"abstract":"<div><h3>Background</h3><div>To evaluate the efficacy and safety of radiotherapy with immune checkpoint inhibitors (ICIs), with or without anti-vascular endothelial growth factor (anti-VEGF) agents, in the treatment of advanced or unresectable hepatocellular carcinoma (HCC).</div></div><div><h3>Methods</h3><div>Databases including Web of Science, PubMed, Embase, Cochrane Library databases, American Society of Clinical Oncology, and European Society for Medical Oncology were systematically searched. The search included publications up to August 31, 2024. Primary outcome measures included objective response rate (ORR), disease control rate (DCR), incidence of treatment-related adverse events (TRAEs), and TRAEs (grade ≥3).</div></div><div><h3>Results</h3><div>Twenty-one articles were included in this study (927 participants). Following RECIST 1.1, for external radiotherapy combined with ICIs, the ORR and DCR were 56 % (95 % CI 0.48–0.64, I²=65.91 %) and 88 % (95 % CI 0.77–0.96, I²=87.19 %), respectively; for yttrium-90 combined with ICI, they were 31 % (95 %CI 0.20–0.43, I²=0 %) and 73 % (95 %CI 0.48–0.92, I²=75.23 %), respectively. According to CTCAE criteria, for external radiotherapy combined with ICIs, the incidence of TRAEs (all grades) was 95 % (95 % CI 0.89–0.98, I²=70.79 %), and the incidence of TRAEs (grades ≥3) was 35 % (95 % CI 0.23–0.48, I²=87.54 %); for yttrium-90 combined with ICIs, they were 78 % (95 %CI 0.48–0.98, I²=88.15 %) and 22 % (95 %CI 0.04–0.47, I²=83.69 %), respectively. Subgroup analyses indicated that sequential therapy demonstrated a higher DCR than concurrent therapy, while the combination of intensity-modulated radiotherapy, ICIs, and anti-VEGF agents showed improved efficacy but was associated with increased toxicity.</div></div><div><h3>Conclusions</h3><div>Radiotherapy combined with ICI demonstrates substantial efficacy and manageable safety in advanced or unresectable HCC. Sequential therapy may enhance therapeutic effectiveness while reducing TRAEs.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"211 ","pages":"Article 104730"},"PeriodicalIF":5.5,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biology of renal cancer tumor thrombus - towards the personalized approach","authors":"Sumit Sharma ,&nbsp;Michał Kunc ,&nbsp;Mieszko Czapliński ,&nbsp;Weronika Łyzińska ,&nbsp;Rafał Pęksa ,&nbsp;Le Qu ,&nbsp;Piotr Radziszewski ,&nbsp;Łukasz Zapała","doi":"10.1016/j.critrevonc.2025.104731","DOIUrl":"10.1016/j.critrevonc.2025.104731","url":null,"abstract":"<div><div>Renal cell carcinoma - related thrombus arising within venous system (venous tumor thrombus, VTT) represents a distinct compartment within cancer, situated at the frontline with the continual interaction with host blood cells. Various host immune blood cells may possibly interact with VTT influencing its biology. While many authors have reviewed the current state-of-the-art of the management of VTT, its biology and microenvironment has not been comprehensively reviewed to date. In this narrative review, we described the current concepts on formation of thrombus, its histopathology, immune microenvironment, genetic and molecular features with potential impact on prognostication and tailored therapy. Although it is the sophisticated and challenging surgery that remains the primary modality in the management of RCC with VTT, recent advances in the research on cancer biology and microenvironment shed some light on the numerous future perspectives. The formation of tumor thrombus is a complex process, understanding of which may trigger onset of novel therapies leading to the improvement of not only oncological results but also patients’ safety in these life-threatening conditions.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"211 ","pages":"Article 104731"},"PeriodicalIF":5.5,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}